Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?

Objectives. To examine whether adjuvant therapy after primary surgery for treatment of early-stage uterine leiomyosarcoma (LMS) improves recurrence and survival rates. Methods. A multisite, retrospective study of women diagnosed with stage I-II high grade LMS from 19902010 was performed. All patients (pts) underwent primary surgery followed by observation (OBS), radiotherapy (RT), or chemotherapy (CT) postoperatively Results. One One hundred eight patients were identified with long-term follow-up; 94 pts (87.0%) had stage land 14(13.0%) had stage II disease. The mean pratient age was 55.4 years and mean BMI was 28.0. Thirty-four (31.5%) patients underwent OBS, 35 (32.4%) received RT, and 39 (36.1%) received chemotherapy. After a median follow-up of 41.8 months, a recurrence was diagnosed in 70.8%. Recurrence was evident in 25/34 (73.5%) OBS, 23/35 (65.7%) RT, and 28/39 (71.8%) of CT cohorts and was not different based on treatment (p = 0.413). However, extra-pelvic recurrences were significantly higher in the RT (952%) than in the OBS (60%) or Cl' (64.3%) cohorts (p = 0.012). Additionally, recurrences were more likely to be successfully treated or palliated in those who initially received CT (p = 0.031). On multivariate analysis, stage (p < 0.001) and chemotherapy (p = 0.045) were associated with overall survival. Conclusions. Women with early-stage, high grade uterine LMS experience high recurrence rates and poor survival outcomes, irrespective of adjuvant therapy. These rates are higher than previously reported in the literature. Although women treated with Cl' had similar recurrence rates as those treated with OBS or RT, treatment with adjuvant chemotherapy may decrease the risk of extra-pelvic recurrence and improve survival. (C) 2013 Elsevier Inc. All rights reserved.